Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: J Thromb Haemost. 2014 Jul 17;12(8):1283–1293. doi: 10.1111/jth.12633

Fig. 3. Phenotypic correction assessment of 2bF8/MGMT-transduced recipients (MOI of 1).

Fig. 3

(A) Tail clip survival test. Tail clipping was performed at least 6 weeks after the final BG/BCNU treatment. Fifteen of 16 transduced recipients pre-conditioned with 660 cGy TBI survived tail clipping. (B) Tail bleeding test. Hemoglobin (Hb) levels were measured before and 6 hours after tail clipping. The level of Hb in each animal before the test was defined as 100%. Five of 12 FVIIInull mice survived beyond 6 hours with only 35% Hb remaining, while all BG/BCNU-treated transduced recipients survived with 69% Hb remaining. (C) ROTEM analysis of whole blood clotting time. The clotting time in transduced BG/BCNU-treated animals was significantly shorter than in FVIIInull controls. These results demonstrate that hemostasis was restored in hemophilia A mice after 2bF8/MGMT gene therapy followed by in vivo selection.